As Japanese drugmaker Eisai this week presented data confirming it had developed the first drug to slow cognitive decline in Alzheimer’s patients, the audience at a conference in San Francisco burst into applause.
Among those in attendance was Lars Lannfelt, a little-known Swedish scientist who invented the groundbreaking drug, known as lecanemab, and will make a fortune if it is approved and successfully marketed.
BioArctic, the company he co-founded in 2003 with Pär Gellerfors, struck a licensing deal on the monoclonal antibody therapy with Eisai in 2007, entitling it to hundreds of millions of dollars in milestone payments and royalties on lecanemab sales.
您已閱讀10%（665字），剩餘90%（5811字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。